145 / 182
FIVE
| 141
Integrated Report 2016
ANNUAL FINANCIAL STATEMENTS
(continued)
SIX
THREE
ONE
FOUR
TWO
Shareholding
June
2016
%
June
2015
%
Subsidiaries
Adcock Ingram Limited
100
100
Adcock Ingram Healthcare Proprietary Limited
100
100
Adcock Ingram Intellectual Property Proprietary Limited
100
100
Adcock Ignram Critical Care Proprietary Limited
100
100
Adcock Ingram International Proprietary Limited
100
100
Tender Loving Care – Hygienic, Cosmetic and Baby Products Proprietary Limited
100
100
Joint ventures
Thembalami Pharmaceuticals Proprietary Limited
50
50
Adcock Ingram Limited (India)
49,9
49,9
Indirect holdings
Adcock Ingram Pharmaceuticals Proprietary Limited
100
100
Premier Pharmaceutical Company Proprietary Limited
100
100
Metamorphosa Proprietary Limited
50
50
Menarini SA Proprietary Limited **
49
49
Novartis Ophthalmics Proprietary Limited **
49
49
Addclin Research Proprietary Limited
100
100
Adcock Ingram Intellectual Property No 1 Proprietary Limited
100
100
Dilwed Investments Proprietary Limited
100
100
Adcock Ingram Namibia Proprietary Limited
100
100
National Renal Care Proprietary Limited
50
50
Pharmalabs (Jersey) Limited
100
100
Datlabs (Private) Limited
100
100
Adcock Ingram Healthcare Private Limited (India)
100
100
Adcock Ingram East Africa Limited
100
100
Ayrton Drug Manufacturing Limited (Ghana)
78,57
78,57
Ayrton Drug Manufacturing Limited (Sierra Leone)
78,57
78,57
Trusts and structured entities
Adcock Ingram Holdings Limited Employee Share Trust (2008)
Mpho ea Bophelo Trust
AdBEE (RF) Limited
*
Ad-Izinyosi Proprietary Limited
*
19 Owner-driver companies (2015: 19 companies)
* Not consolidated – refer accounting policies
** Regarded as subsidiaries
ANNEXURE H –
INTEREST IN SUBSIDIARY COMPANIES AND JOINT VENTURES